Article Versions Notes

Blondonnet R, Simand L-A, Vidal P, Borao L, Bourguignon N, Morand D, Bernard L, Roszyk L, Audard J, Godet T, et al. Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial. Journal of Clinical Medicine. 2022; 11(10):2796. https://doi.org/10.3390/jcm11102796

Blondonnet, Raiko, Laure-Anne Simand, Perine Vidal, Lucile Borao, Nathalie Bourguignon, Dominique Morand, Lise Bernard, Laurence Roszyk, Jules Audard, Thomas Godet, and et al. 2022. "Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial" Journal of Clinical Medicine 11, no. 10: 2796. https://doi.org/10.3390/jcm11102796

Blondonnet, R., Simand, L.-A., Vidal, P., Borao, L., Bourguignon, N., Morand, D., Bernard, L., Roszyk, L., Audard, J., Godet, T., Monsel, A., Garnier, M., Quesnel, C., Bazin, J.-E., Sapin, V., Bastarache, J. A., Ware, L. B., Hughes, C. G., Pandharipande, P. P., ... on behalf of the SESAR Collaborative Group. (2022). Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial. Journal of Clinical Medicine, 11(10), 2796. https://doi.org/10.3390/jcm11102796